A systematic review and meta-analysis, published in The Lancet Oncology, provides new insights into which patients benefit most from adding docetaxel to androgen deprivation therapy (ADT). The data, pooled from major randomized trials (GETUG-AFU15, CHAARTED, and STAMPEDE), show a clear survival advantage but suggest the greatest benefit is seen in patients with high-volume and T4 disease.
Key Findings:
Overall survival significantly improved (HR 0.79, p<0.0001)
Progression-free survival and failure-free survival also showed strong benefits
The highest survival gains were seen in patients with high-volume, clinical T4 disease
Minimal or no benefit was observed in low-volume, metachronous disease
These results provide crucial guidance for treatment decisions in metastatic hormone-sensitive prostate cancer.
A huge acknowledgment to the experts behind this meta-analysis for their contributions to refining treatment strategies.
Read the full study: https://lnkd.in/ewASC6GW
